Immediate Impact

26 from Science/Nature 69 standout
Sub-graph 1 of 20

Citing Papers

Targeting HER2-positive breast cancer: advances and future directions
2022 Standout
Lipid Nanoparticles─From Liposomes to mRNA Vaccine Delivery, a Landscape of Research Diversity and Advancement
2021 Standout
2 intermediate papers

Works of Jay Overholser being referenced

Phase I Immunotherapy Trial with Two Chimeric HER-2 B-Cell Peptide Vaccines Emulsified in Montanide ISA 720VG and Nor-MDP Adjuvant in Patients with Advanced Solid Tumors
2019
Selective inhibition of vascular endothelial growth factor (VEGF) receptor 2 (KDR/Flk-1) activity by a monoclonal anti-VEGF antibody blocks tumor growth in mice.
2000

Author Peers

Author Last Decade Papers Cites
Jay Overholser 433 351 136 178 16 750
Azadeh Arabzadeh 527 345 160 255 20 977
S. Virudachalam 644 354 201 143 17 986
Hillary J. Millar 481 348 81 242 14 756
D. Fan 401 358 128 97 23 796
Luigi Manenti 328 454 77 278 18 859
Karen Morrison 295 228 78 174 23 811
L Deneux 377 340 130 313 17 826
Ángel Santiago 689 325 78 137 16 895
Doreen LePage 442 288 131 162 19 871
Jason R. Neil 560 364 111 75 14 922

All Works

Loading papers...

Rankless by CCL
2026